Medinotec Inc. Reports 7% Revenue Growth to $9.73 Million for Fiscal Year Ending February 28, 2026

Medinotec Inc. reported a revenue increase of 7% for the fiscal year ending February 28, 2026, totaling $9.73 million, compared to $9.11 million in the previous year. This growth was primarily driven by enhanced distribution partnerships in South Africa, which significantly boosted sales volumes in the company's cardiology and dialysis product lines. Distribution agreement sales outside the United States rose to $8.14 million, up from $7.57 million, while internally designed and manufactured sales also saw a modest increase to $975,969 from $863,337. However, U.S. sales of internally manufactured products decreased to $611,860 from $678,105, attributed to timing issues with customer orders.

The company's net income for the fiscal year was $794,502, a decline from $2.16 million in the prior year, largely due to a significant rise in operating expenses, which totaled $4.03 million compared to $1.63 million in the previous year. The increase in operating expenses was driven by higher selling, general, and administrative costs, as well as increased research and development expenditures. Notably, selling expenses surged to $1.49 million from $113,194, primarily due to costs associated with distributor support in South Africa.

Medinotec's operational metrics indicate a workforce of 48 employees and independent contractors as of February 28, 2026, with plans for further expansion into the U.S. market following the FDA clearance of its Trachealator and Outflo products. The company has established distribution agreements in approximately 45 countries, with a focus on expanding its presence in the U.S. and other international markets. The company aims to reduce its reliance on a limited number of customers, particularly DISA Life Sciences, which accounted for approximately 89% of total revenue in the fiscal year.

Looking ahead, Medinotec anticipates continued revenue growth driven by the launch of new products and expansion into additional markets. However, the company faces several risks, including regulatory challenges, geopolitical tensions, and currency fluctuations, particularly given its reliance on South African operations. Management has expressed confidence in its ability to navigate these challenges while maintaining a focus on operational efficiency and strategic growth initiatives. The company has sufficient cash reserves to support its operations and plans to explore additional funding options for future expansion efforts.